Adamas Pharmaceuticals, Inc.: cash_and_equivalents

Value{"amount": 58936000, "concept": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "currency": "USD"}
Period (as of 2019-03-31)
Statuscurrent
EntityAdamas Pharmaceuticals, Inc.
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference: 0001328143-19-000026 · Open the official SEC filing →
Retrieved: 2026-08-19T12:42:20.451056+02:00
Raw response sha256: f7bde1a401b286c74a2fd824ee1df541…
Also addressable by official identifiers: https://factanker.com/fact/sec/cik-0001328143/cash-and-equivalents/2019-03-31 (CIK, metric, reporting date)
Cite as: FACTANKER, https://factanker.com/fact/6a7f019c-ecd9-4b94-8b75-75facecd39d9

History

From the Record
32 US software companies haven’t lost money in a decade. One of them is steadier than all the rest.
Read the findingSearch 53 million companies